Why the study?
Does a polymer-free Biolimus-A9-coated stent with 1-month DAPT improve efficacy and safety compared to a bare-metal stent in high bleeding risk patients with acute coronary syndrome undergoing PCI?
Does a polymer-free Biolimus-A9-coated stent with 1-month DAPT improve efficacy and safety compared to a bare-metal stent in high bleeding risk patients with acute coronary syndrome undergoing PCI?
In high bleeding risk patients with ACS, a polymer-free Biolimus-A9-coated stent with 1-month DAPT is superior to a bare-metal stent for both efficacy and safety, suggesting BMS should no longer be recommended for this indication.
Answers are grounded in this paper and cite their sources.
Supports BA9-DCS over BMS in high-bleeding-risk ACS; challenges continued BMS use with short DAPT.
Aims: Although a true clinical challenge, high bleeding risk patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) have never been specifically studied. Leaders Free ACS, a pre-specified Leaders Free sub-study, determined efficacy, and safety of a combination of 1-month dual anti-platelet therapy (DAPT) with implantation of either a polymer-free Biolimus-A9-coated stent (BA9-DCS) or a bare-metal stent (BMS) in these patients. Methods and results: Leaders Free included 2466 patients undergoing PCI who had at least 1 of 13 pre-defined factors for an increased bleeding risk. Of these, 659 ACS patients were included in this analysis (BA9-DCS 330, BMS 329). At 12-month follow-up, treatment with the BA9-DCS was more effective (clinically driven target-lesion revascularization 3.9 vs. 9.0%, P = 0.009) and safer (cumulative incidence of cardiac death, myocardial infarction, or definite or probable stent thrombosis 9.3 vs. 18.5%, P = 0.001), driven by significantly lower rates of cardiac mortality (3.4 vs. 6.9%, P = 0.049) and myocardial infarction (6.9 vs. 13.8%, P = 0.005). Conclusion: We believe that the results of this sub-analysis from the Leaders Free trial are likely to significantly impact clinical practice for high bleeding risk patients presenting with an ACS: the use of a BMS can, in our view, no longer be recommended, and, given the paucity of available data for second-generation DES with shortened DAPT in these patients, the BA9-DCS should currently be considered as the device with the strongest evidence to support its use for this indication.
No takes yet. Share an insight, caveat, or question.
Naber et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: